Our ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a highly immunogenic member of the MAGE-A family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher grade tumors.

Based on our ongoing preclinical evaluation, we believe our ADP-A2M10 (MAGE-A10) TCR therapeutic candidate has the potential ability to bind target peptides from multiple cancer types. Clinical trials to evaluate the safety and anti-tumor activity of our ADP-A2M10 (MAGE-A10) TCR therapy are open for certain patients with lung cancer, bladder, melanoma and head and neck cancers.